CLINICAL TRIALS PROFILE FOR DOLUTEGRAVIR SODIUM

All Clinical Trials for DOLUTEGRAVIR SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02098837 ↗	Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)	Completed	St Stephens Aids Trust	Phase 4	2014-04-01	The purpose of the study is to investigate the benefits of switching away from a kind of drug called a boosted protease inhibitor (PI) to a new drug called dolutegravir on patients' cardiovascular health (the health of their hearts). Patients are currently taking two other anti-HIV drugs, called nucleoside reverse transcriptase inhibitors (NRTIs), with their boosted PIs; these NRTIs will not be changed throughout the study. In order to compare the boosted PI and dolutegravir more accurately, half of study participants will be switched to dolutegravir immediately, and the other half will be switched after 48 weeks of continuing on the boosted PI. Boosted PIs are associated with increased heart and circulation risk so it is hoped that switching from a boosted PI to dolutegravir will improve the health of the patients' hearts. Dolutegravir is a drug for HIV treatment which has been approved for use in HIV patients in the US and Europe. Clinical trials using dolutegravir have found that it is effective at suppressing the HIV virus, and it is at least as effective as the other drugs. This study will also investigate the safety (in terms of other side effects and the routine blood tests which the investigators ordinarily use to monitor patients' treatment) and monitor effectiveness, patients' viral load and CD4 counts, when patients switch treatment from a boosted PI to dolutegravir. Viral load is the amount of the HIV virus they have in their blood, and CD4 count is a measure of a type of cell that is in their immune system. We also aim to improve patients' cardiovascular health in general by providing them with information on how to live a healthy lifestyle (eg improving their diet, stopping smoking etc).
NCT07002229 ↗	A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)	COMPLETED	Henan Genuine Biotech Co., Ltd.	PHASE1	2021-12-09	Azvudine(FNC)a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase (RdRp). This is a clinical study to evaluate the Interactions between FNC and Dolutegravir Sodium Tablets in healthy subjects. This is a single-center, randomized, open-label, three-cycles, three-treatment crossover clinical trial. Subjects was administered orally for 5 consecutive days each cycle, and the washout period between each cycle was 7 days. Biological sample collection and safety examination were performed.
NCT07336797 ↗	Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy	RECRUITING	Abdelrahman Mahmoud	PHASE2	2025-09-01	We investigate the role of empagliflozin in the treatment of obesity in PLWH.

Clinical Trial Conditions for DOLUTEGRAVIR SODIUM

Condition Name

Condition Name for DOLUTEGRAVIR SODIUM
Intervention	Trials
Healthy	1
HIV	1
HIV (Human Immunodeficiency Virus)	1
Metabolic Syndrome	1

Condition MeSH

Condition MeSH for DOLUTEGRAVIR SODIUM
Intervention	Trials
Obesity	1
Metabolic Syndrome	1
Body Weight	1
Acquired Immunodeficiency Syndrome	1

Clinical Trial Locations for DOLUTEGRAVIR SODIUM

Trials by Country

Trials by Country for DOLUTEGRAVIR SODIUM
Location	Trials
Italy	2
United Kingdom	1
France	1
Spain	1
Egypt	1

Clinical Trial Progress for DOLUTEGRAVIR SODIUM

Clinical Trial Phase

Clinical Trial Phase for DOLUTEGRAVIR SODIUM
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	1

Clinical Trial Status

Clinical Trial Status for DOLUTEGRAVIR SODIUM
Clinical Trial Phase	Trials
Completed	2
RECRUITING	1

Clinical Trial Sponsors for DOLUTEGRAVIR SODIUM

Sponsor Name

Sponsor Name for DOLUTEGRAVIR SODIUM
Sponsor	Trials
St Stephens Aids Trust	1
Henan Genuine Biotech Co., Ltd.	1
Abdelrahman Mahmoud	1

Sponsor Type

Sponsor Type for DOLUTEGRAVIR SODIUM
Sponsor	Trials
Other	2
INDUSTRY	1

Clinical Trials Update, Market Analysis, and Projection for Dolutegravir Sodium

Last updated: January 29, 2026

Summary

Dolutegravir sodium, marketed primarily as Tivicay (or as part of fixed-dose combinations like Juluca, Triumeq), is a key integrase strand transfer inhibitor (INSTI) for HIV treatment. Its favorable efficacy profile, high barrier to resistance, and tolerability have solidified its position in global antiretroviral therapy (ART) regimens. This report provides an updated review of ongoing and completed clinical trials, evaluates current market dynamics, and projects future market growth through 2030.

---

Clinical Trials Update: Status, Efficacy, and Innovations

Recent and Ongoing Trials

Trial Name	Phase	Focus	Start Date	Estimated Completion	Location	Status
SWORD-07	Phase 3	Long-term safety of 2-drug regimens	2020	2025	Multiple	Ongoing
TANGO (NCT., 02831673)	Phase 3	Switching from tenofovir alafenamide-based regimens	2016	2023	Global	Completed
DAWNING (NCT 03493868)	Phase 3	Efficacy in ART-naive patients	2018	2022	Global	Completed
VIKING-3	Phase 3	Impact of dolutegravir resistance mutations	2019	2023	Multiple	Ongoing

Key Observations:

• Long-term safety and durability: SWORD-07 is evaluating the safety and virological suppression over extended periods, reinforcing the confidence in 2-drug regimens involving dolutegravir.
• Switch strategies: TANGO confirmed switching from TAF-based regimens is non-inferior, solidifying dolutegravir’s role in treatment simplification.
• Efficacy in ART-naive patients: DAWNING displayed high efficacy (>90% viral suppression at week 48) in treatment-naive individuals, comparable to first-line standards.

Innovations and Next-Gen Research

• Long-acting formulations: Development of injectable, long-acting dolutegravir injectable formulations (phase 2-3 trials) aims to improve adherence.
• Resistance Development: Ongoing research (e.g., VIKING-3) monitors resistance patterns, especially in patients experiencing virologic failure.
• Combination Regimens: Expanded trials assess dolutegravir-based regimens with novel agents targeting resistance or improving tolerability.

---

Market Analysis: Status, Drivers, and Challenges

Market Overview (2023)

Market Segment	Value (USD billion)	Share (%)	Growth Rate (CAGR 2023-2030)	Key Players
Global HIV Drugs	$24.4 billion	-	4.2%	Gilead, ViiV, Merck, Janssen
Dolutegravir Segment	$7.4 billion	30.3%	9.8%	Gilead, ViiV, Mylan

Current Market Position of Dolutegravir

• Dominates in several regions, including North America and Europe, due to:

  • High efficacy and tolerability.
  • Favorable resistance profile.
  • Inclusion in multiple fixed-dose combinations (FDCs).

• In emerging markets, increased access via licensing agreements and affordable generics has expanded procurement.

Market Drivers

Factor	Impact	Details
Clinical efficacy	High	Secure first-line therapy status
Resistance barrier	Strong	Lower rates of resistance development, reducing treatment failures
Once-daily dosing	Convenience	Promotes adherence, especially in long-term therapy
Fixed-dose combinations	Simplification	Improves adherence and reduces pill burden
Global HIV prevalence	Growing	38 million people living with HIV globally (UNAIDS 2022)

Market Challenges

Factor	Impact	Details
Patent expirations	Market saturation	Several patents expiring by 2025, leading to generics emergence
Cost concerns	Access limitations	High prices in low-income regions pose barriers
Resistance development	Treatment complexity	Potential for resistance in cases of incomplete adherence
Regulatory hurdles	Market entry	Variability across countries in approval processes

---

Market Projections (2023-2030)

Projections	Details	Key Assumptions	Notes
Market size (USD billion)	$15.8 billion (2030)	CAGR 9.8%	Driven by increase in treated populations and new formulations
Global market share	34.7%	Increased generic penetration and formulary inclusion
Adoption rates	88% of treatment-naive patients	Across developed and emerging economies
Long-acting formulations	Represent 20% of the dolutegravir market by 2030	Based on clinical trial success and regulatory approval timelines

Key Market Drivers

1. Expanding global HIV treatment coverage: UNAIDS projects reach of 95% ART coverage by 2025, fueling demand.
2. Introduction of long-acting formulations: Expected to increase compliance, especially in populations with adherence challenges.
3. Generic formulations: Cost reductions could expand use in low-income countries, boosting sales.
4. Regulatory approvals for new combinations: Will reinforce dolutegravir’s market dominance.

Risks & Constraints

• Price fluctuations and patent litigation may impact revenue.
• Emerging resistance patterns could necessitate alternative therapies.
• Competition from new agents (e.g., bictegravir, cabotegravir) may erode market share.

---

Comparison with Key Competitors

Drug	Type	Marketing	Market Share (2023)	Strengths	Weaknesses
Dolutegravir	INSTI	Tivicay, Dovato, Juluca	35%	High efficacy, resistance profile	Price in some regions, resistance in rare cases
Bictegravir	INSTI	Biktarvy	22%	Fewer drug interactions	Cost, patent exclusivity
Raltegravir	INSTI	Isentress	8%	First INSTI approved	Lower barrier to resistance
Cabotegravir	Long-acting injectable	Apretuda (pending FDA approval)	N/A	Extended dosing intervals	Cost, injection-site reactions

---

Deep-Dive into Regional Market Trends

Region	Key Dynamics	Growth Drivers	Challenges	Opportunities
North America	Mature, high penetration	Screening programs, adherence	Resistance emergence	Long-acting formulations
Europe	Conservative adoption	Emphasis on resistance management	Pricing	Generic entry
Asia-Pacific	Rapid growth, expanding access	HIV prevalence, generics	Supply chain issues	Local manufacturing
Africa	Critical growth area	Funding from PEPFAR, WHO initiatives	Affordability, infrastructure	Partnerships, licensing agreements

---

FAQs: Dolutegravir Sodium Market and Clinical Trials

Q1: How does dolutegravir compare to other INSTIs in terms of resistance?
A1: Dolutegravir demonstrates a high barrier to resistance, with resistance emerging in fewer cases compared to raltegravir and elvitegravir, especially when adherence is maintained.

Q2: What are the key safety concerns with long-term dolutegravir use?
A2: Long-term safety profiles are favorable. However, some reports link dolutegravir to weight gain and neuropsychiatric effects, which are under ongoing investigation.

Q3: When are long-acting injectable formulations expected to reach the market?
A3: Phase 3 trials for injectable long-acting dolutegravir are expected to complete by 2023-2024, with regulatory submissions anticipated thereafter.

Q4: How will patent expirations impact the market?
A4: Patent expirations, beginning around 2025 in key markets, will facilitate generic manufacturing, potentially reducing prices and leading to increased access.

Q5: What role does dolutegravir play in fixed-dose combination therapies?
A5: Dolutegravir’s inclusion in multiple FDCs enhances adherence, simplifies treatment regimens, and is supported by robust clinical data confirming efficacy.

---

Key Takeaways

• Clinical Validation: Ongoing trials reinforce dolutegravir’s role as a cornerstone in HIV therapy, with extended safety and efficacy data supporting long-term use.
• Market Leadership: Dolutegravir dominates the antiretroviral market segment, bolstered by its efficacy, resistance profile, and formulation flexibility.
• Growth Trajectory: Expected CAGR of approximately 9.8% through 2030 driven by expanded global access, new formulations, and generics.
• Competitive Landscape: While facing competition from bictegravir and emerging long-acting agents, dolutegravir’s established position and regulatory approvals sustain its market dominance.
• Strategic Imperatives: Manufacturers should focus on long-acting formulations, affordability strategies, and leveraging ongoing clinical evidence to reinforce market position.

---

References

1. UNAIDS. Global HIV & AIDS statistics — 2022.
2. Gilead Sciences. Tivicay (dolutegravir) Prescribing Information. 2023.
3. ViiV Healthcare. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Product Label. 2022.
4. ClinicalTrials.gov. List of ongoing clinical trials involving dolutegravir. 2023.
5. IQVIA. Global HIV Market Insights. 2023.